These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 35737858)

  • 1. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.
    Kim N; Wang J; Burudpakdee C; Song Y; Ramasamy A; Xie Y; Sun R; Kumar N; Wu EQ; Sullivan SD
    J Manag Care Spec Pharm; 2022 Jul; 28(7):740-752. PubMed ID: 35737858
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study.
    Watkins S; Toliver JC; Kim N; Whitmire S; Garvey WT
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1066-1079. PubMed ID: 35856489
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.
    Olivieri AV; Muratov S; Larsen S; Luckevich M; Chan K; Lamotte M; Lau DCW
    Int J Obes (Lond); 2024 May; 48(5):683-693. PubMed ID: 38291203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
    Mital S; Nguyen HV
    JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.
    Sandhu H; Xu W; Olivieri AV; Lübker C; Smith I; Antavalis V
    Adv Ther; 2023 Mar; 40(3):1282-1291. PubMed ID: 36630047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal.
    Silva Miguel L; Soares M; Olivieri A; Sampaio F; Lamotte M; Shukla S; Conde V; Freitas P; Costa J; Borges M
    Diabetol Metab Syndr; 2024 Apr; 16(1):97. PubMed ID: 38689367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
    Lim F; Bellows BK; Tan SX; Aziz Z; Woo Baidal JA; Kelly AS; Hur C
    JAMA Netw Open; 2023 Aug; 6(8):e2329178. PubMed ID: 37651143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.
    Haseeb M; Chhatwal J; Xiao J; Jirapinyo P; Thompson CC
    JAMA Netw Open; 2024 Apr; 7(4):e246221. PubMed ID: 38607627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
    Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
    J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
    [No Abstract]   [Full Text] [Related]  

  • 16. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
    Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
    Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
    Cui J; Klepser DG; McAdam-Marx C
    J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.
    Taieb A; Stein Gold L; Feldman SR; Dansk V; Bertranou E
    J Manag Care Spec Pharm; 2016 Jun; 22(6):654-65. PubMed ID: 27231793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.
    Alshahawey M; Ghazy M; El Morshedy M; El Said NO
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3365-3374. PubMed ID: 38766793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.